Vaginal Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033
Vaginal cancer is a rare gynecological malignancy, accounting for only 1-2% of all gynecologic neoplasms. Most cases (90%) are squamous cell carcinomas, while 5% are adenocarcinomas. Squamous cell carcinomas spread superficially, with the lungs and liver common sites of distant metastasis. The human papillomavirus (HPV) is a known cause of vaginal cancer, with subtypes HPV 16 and 18 being the primary types responsible. The viral proteins E6 and E7 interfere with critical cell cycle points and contribute to HPV-related neoplasia. HPV infection can lead to the development of high-grade squamous intraepithelial lesions (HGSIL) and carcinoma of the vagina. Primary melanomas of the female reproductive system are rare and aggressive cancers, with the vulva being the most common site, followed by the vagina and, rarely, the cervix. The stage at the time of diagnosis is the most important prognostic factor for vaginal cancer, with 5-year relative survival rates of 96% for stage 0, 64-84% for stage I, 53-58% for stage II, 36% for stage III, and 18-36% for stage IV. Other factors that negatively impact prognosis include tumor size >4 cm, older age, and tumor location outside the upper third of the vagina. High-risk HPV DNA and low MIB-1 index have been found to have a favorable prognostic value.
- In Germany, the incidence of vaginal cancer was estimated to be 0.6-1.0 cases per woman.
Thelansis’s “Vaginal Cancer Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Vaginal Cancer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Vaginal Cancer across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Vaginal Cancer Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment